A Study of LY2090314 in Patients With Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a recommended Phase 2 dose and dosing regimen of
LY2090314 in combination with pemetrexed and carboplatin in patients with advanced/metastatic
cancer. Part A of this study will consist of dose escalation of the study regimen, and Part B
will consist of an expanded cohort to confirm the dose provided from Part A.